NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp · Executive Compensation
$1.53
-0.03 (-2.24%)
At close · Sep 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$14.20M
Shares
9.11M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dave Rosa | Chief Executive Officer and President | $1,154,436 |
| Christoper Volker | Chief Operating Officer | $687,373 |
| Ron McClurg | Chief Financial Officer | $523,822 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dave Rosa | Chief Executive Officer and President | $1,995,745 |
| Christoper Volker | Chief Operating Officer | $712,147 |
| Ron McClurg | Chief Financial Officer | $598,553 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dave Rosa | Chief Executive Officer and President | $989,558 |
| Steve Mertens | Chief Technology Officer | $457,714 |
| Ron McClurg | Chief Financial Officer | $390,157 |
| Christoper Volker | Chief Operating Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dave Rosa | Chief Executive Officer and President | $1,186,410 |
| Steve Mertens | Chief Technology Officer | $393,644 |
| Ron McClurg | Chief Financial Officer | $375,563 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dave Rosa | Chief Executive Officer and President | $1,889,351 |
| Ron McClurg | Chief Financial Officer | $522,529 |
| Steve Mertens | Chief Technology Officer | $371,138 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dave Rosa | Chief Executive Officer and President | $1,122,891 |
| Steve Mertens | Chief Technology Officer | $288,247 |
| Mark Christianson | Business Development Director, Medical Sales Liaison | $260,848 |
| Ron McClurg | Chief Financial Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dave Rosa | Chief Executive Officer and President | $558,166 |
| Steve Mertens | Chief Technology Officer | $291,391 |
| Mark Christianson | Business Development Director, Medical Sales Liaison | $259,493 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christopher Volker | Chief Financial Officer | Appointed | 2026-04-30 |
| Ronald McClurg | Chief Financial Officer | Retired | 2026-04-30 |
| Jason R. Mills | Class I director | Appointed | 2025-12-22 |